PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 15516294-15 2004 Quetiapine is extensively metabolized by CYP 3A4 and CYP 2D6 and to a lesser extent by CYP 3A7, CYP 3A5, and CYP 2C19. Quetiapine Fumarate 0-10 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 41-48 12186270-3 2002 Olanzapine is both conjugated and oxidized (mainly by CYP1A2), while quetiapine and zotepine primarily undergo CYP3A4-mediated oxidation. Quetiapine Fumarate 69-79 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 111-117 12670127-5 2003 Quetiapine and ziprasidone are metabolized by CYP3A4. Quetiapine Fumarate 0-10 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 46-52 10422890-7 1999 Quetiapine is metabolised by CYP3A4 and sertindole by CYP2D6. Quetiapine Fumarate 0-10 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 29-35 11051217-9 2000 Quetiapine is metabolised by the cytochrome P450 3A4 isoenzyme, and the dose may need to be adjusted if quetiapine is co-administered with drugs which affect the activity of this isoenzyme. Quetiapine Fumarate 0-10 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 33-52 11051217-9 2000 Quetiapine is metabolised by the cytochrome P450 3A4 isoenzyme, and the dose may need to be adjusted if quetiapine is co-administered with drugs which affect the activity of this isoenzyme. Quetiapine Fumarate 104-114 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 33-52 10917381-8 2000 A contributing factor in this case may have been the concomitant administration of metronidazole, which inhibits the cytochrome P450 enzyme (CYP3A4) also responsible for the metabolism of quetiapine. Quetiapine Fumarate 188-198 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 141-147 10843459-5 2000 However, for the thienobenzodiazepine olanzapine a main metabolic route is direct conjugation at the benzodiazepine nucleus, whereas for the dibenzothiazepine quetiapine and the dibenzothiepine zotepine it is CYP3A4-mediated oxidation, leading to sulfoxidation, hydroxylation and dealkylation for quetiapine, but N-demethylation to the active nor-derivative for zotepine. Quetiapine Fumarate 159-169 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 209-215 34683865-6 2021 We demonstrated the existence of quetiapine derivatives with a catechol-like structure (7,8-dihydroxi-quetiapine and 7,8-dihydroxi-N-desalkyl-quetiapine), which would be COMT metabolites and would explain quetiapine accumulation through CYP2D6 and CYP3A4 negative feedback. Quetiapine Fumarate 33-43 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 248-254 34683865-6 2021 We demonstrated the existence of quetiapine derivatives with a catechol-like structure (7,8-dihydroxi-quetiapine and 7,8-dihydroxi-N-desalkyl-quetiapine), which would be COMT metabolites and would explain quetiapine accumulation through CYP2D6 and CYP3A4 negative feedback. Quetiapine Fumarate 205-215 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 248-254 33199804-5 2020 Quetiapine was incubated in metabolically competent human liver cell models (HepaRG) for different times (0 h, 3 h, 8 h, 24 h) with or without cytochrom P450 (CYP) inhibitor (ketoconazole as CYP3A4/5 inhibitor and quinidine as CYP2D6 inhibitor), in order to study its metabolism kinetic and pathways. Quetiapine Fumarate 0-10 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 191-199 34440433-7 2021 The pharmacogenetic variables response to serotonin-norepinephrine reuptake inhibitors (SNRIs) (ABCB1) and reduced metabolism of quetiapine (CYP3A4) predicted patient response to these medications, respectively. Quetiapine Fumarate 129-139 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 141-147 35165231-4 2022 We present a case of a patient taking 150 mg venlafaxine (CYP2D6/3A substrate), 300 mg quetiapine (CYP3A substrate), and a high amount of kratom (~90 g) daily. Quetiapine Fumarate 87-97 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 99-104 34204223-2 2021 The extensive hepatic metabolism of quetiapine is mainly attributed to cytochrome P450 3A4 (CYP3A4). Quetiapine Fumarate 36-46 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 71-90 34204223-2 2021 The extensive hepatic metabolism of quetiapine is mainly attributed to cytochrome P450 3A4 (CYP3A4). Quetiapine Fumarate 36-46 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 92-98 35380747-7 2022 RESULTS: We observed a negative relationship between vitamin D and dose-adjusted antipsychotic drug concentrations, which was particularly pronounced for drugs which are predominantly metabolized via CYP3A4 (i.e., aripiprazole and quetiapine). Quetiapine Fumarate 231-241 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 200-206 33199804-7 2020 Molecular networking approach on LC-HRMS/MS data allowed to quickly visualize the quetiapine metabolism kinetics and determine the major metabolic pathways (CYP3A4/5 and/or CYP2D6) involved in metabolite formation. Quetiapine Fumarate 82-92 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 157-165 32446424-4 2020 The high activity of the CYP3A4 isoenzyme was manifested by fast metabolism for quetiapine and diazepam, which took more than 1 year to normalize after the inducer, phenytoin, was stopped. Quetiapine Fumarate 80-90 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 25-31 32276526-9 2020 Quetiapine exclusively suffered (100%) from potential DDIs with amlodipine, buspirone, omeprazole or topiramate via the CYP3A4 isoform. Quetiapine Fumarate 0-10 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 120-126 32910451-6 2020 It is striking that carbamazepine and quetiapine have a strong pharmacokinetic interaction via the metabolizing liver enzyme, CYP3A4. Quetiapine Fumarate 38-48 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 126-132 29369597-2 2017 A series of studies has shown that concurrent use of carbamazepine decreases quetiapine serum level due to induction of CYP3A enzymes by carbamazepine. Quetiapine Fumarate 77-87 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 120-125 29702137-11 2018 This may be a consequence of a reduced metabolism of venlafaxine to the inactive metabolite N-desmethylvenlafaxine via CYP3A4, the main metabolizing enzyme for quetiapine, and a shift towards a higher proportion of the active metabolite ODVEN. Quetiapine Fumarate 160-170 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 119-125 28340451-7 2017 Enzalutamide may decrease plasma levels of CYP3A4, 2C9 and 2C19 substrates including disopiramide, quetiapine, quinidine and warfarin. Quetiapine Fumarate 99-109 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 43-49 28585378-0 2017 4beta-Hydroxycholesterol level significantly correlates with steady-state serum concentration of the CYP3A4 substrate quetiapine in psychiatric patients. Quetiapine Fumarate 118-128 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 101-107 28585378-2 2017 The aim of this study was to investigate the correlation between 4betaOHC levels and steady-state concentrations (Css) of quetiapine, a CYP3A4 substrate with high presystemic metabolism, in psychiatric patients. Quetiapine Fumarate 122-132 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 136-142 24092799-2 2014 A drug-drug interaction is the suspected cause whereby CYP3A4 inhibition by boceprevir led to increased exposures of doxazosin, tamsulosin, and/or quetiapine, resulting in additional alpha-adrenergic blockade. Quetiapine Fumarate 147-157 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 55-61 25868121-3 2015 Quetiapine, an antipsychotic metabolized by only CYP3A4, displayed higher serum levels in CYP3A4*22 carriers. Quetiapine Fumarate 0-10 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 49-55 25868121-3 2015 Quetiapine, an antipsychotic metabolized by only CYP3A4, displayed higher serum levels in CYP3A4*22 carriers. Quetiapine Fumarate 0-10 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 90-96 24525658-0 2014 The influence of the CYP3A4*22 polymorphism on serum concentration of quetiapine in psychiatric patients. Quetiapine Fumarate 70-80 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 21-27 24525658-4 2014 We investigated to which degree the CYP3A4*22 SNP affects serum concentrations of patients receiving quetiapine, a drug exclusively metabolized by CYP3A4. Quetiapine Fumarate 101-111 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 36-42 24525658-4 2014 We investigated to which degree the CYP3A4*22 SNP affects serum concentrations of patients receiving quetiapine, a drug exclusively metabolized by CYP3A4. Quetiapine Fumarate 101-111 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 147-153 24525658-7 2014 RESULTS: Carriers of the CYP3A4*22 allele (*1/*22 and *22/*22, n = 31) had 2.5-fold higher serum levels of quetiapine than did wild-type patients (n = 207; P = 0.03) when using a comparable dose (median, 300 mg/d for both wild-type and carriers; P = 0.67). Quetiapine Fumarate 107-117 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 25-31 24525658-10 2014 CONCLUSION: Being a carrier of the CYP3A4*22 allele increases the serum concentration of quetiapine at comparable doses. Quetiapine Fumarate 89-99 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 35-41 24797229-5 2014 These models can predict well the effects of CYP3A4 inhibition and induction on the PK of quetiapine, the PK profile of quetiapine IR in children and adults, and the PK profile of quetiapine XR in adults. Quetiapine Fumarate 90-100 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 45-51 24797229-5 2014 These models can predict well the effects of CYP3A4 inhibition and induction on the PK of quetiapine, the PK profile of quetiapine IR in children and adults, and the PK profile of quetiapine XR in adults. Quetiapine Fumarate 120-130 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 45-51 24797229-5 2014 These models can predict well the effects of CYP3A4 inhibition and induction on the PK of quetiapine, the PK profile of quetiapine IR in children and adults, and the PK profile of quetiapine XR in adults. Quetiapine Fumarate 120-130 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 45-51 22066308-19 2011 Quetiapine is metabolised by cytochrome P450 isoenzyme CYP3A4, creating a high risk of pharmacokinetic interactions. Quetiapine Fumarate 0-10 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 55-61 23230007-2 2013 Quetiapine is predominantly metabolised by cytochrome P450 3A4 (CYP3A4) and to a lesser extent by CYP2D6. Quetiapine Fumarate 0-10 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 43-62 23230007-2 2013 Quetiapine is predominantly metabolised by cytochrome P450 3A4 (CYP3A4) and to a lesser extent by CYP2D6. Quetiapine Fumarate 0-10 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 64-70 23230007-4 2013 The aim of the present study is to evaluate if the use of high dosages of quetiapine in some patients, as compared to patients treated with a dosage in the licensed range (up to 800 mg/day), could be explained by a high activity of CYP3A4 and/or of CYP2D6. Quetiapine Fumarate 74-84 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 232-238 21903893-2 2012 This open-label study in 37 adults with schizophrenia evaluated whether a drug-drug interaction occurs between armodafinil (a moderate CYP3A4 inducer) and the atypical antipsychotic quetiapine (primarily metabolized by CYP3A4). Quetiapine Fumarate 182-192 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 219-225 24240480-2 2014 Quetiapine is metabolized by CYP3A enzymes including CYP3A5 and is a substrate of P-glycoprotein, an efflux drug transporter encoded by the ABCB1 gene. Quetiapine Fumarate 0-10 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 29-34 19022943-0 2009 Metabolism of quetiapine by CYP3A4 and CYP3A5 in presence or absence of cytochrome B5. Quetiapine Fumarate 14-24 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 28-34 19022943-1 2009 The antipsychotic drug quetiapine is extensively metabolized by CYP3A4, but little is known about the possible influence of the polymorphic enzyme CYP3A5. Quetiapine Fumarate 23-33 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 64-70 19022943-2 2009 This in vitro study investigated the relative importance of CYP3A4 and CYP3A5 in the metabolism of quetiapine and compared the metabolic pattern by the two enzymes, in the presence or absence of cytochrome b(5). Quetiapine Fumarate 99-109 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 60-66 19022943-3 2009 Intrinsic clearance (CL(int)) of quetiapine was determined by the substrate depletion approach in CYP3A4 and CYP3A5 insect cell microsomes with or without coexpressed cytochrome b(5). Quetiapine Fumarate 33-43 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 98-104 19022943-5 2009 CL(int) of quetiapine by CYP3A5 was less than 35% relative to CYP3A4. Quetiapine Fumarate 11-21 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 62-68 19022943-7 2009 Metabolism of quetiapine by CYP3A5 revealed a different metabolic pattern compared with CYP3A4. Quetiapine Fumarate 14-24 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 88-94 19022943-10 2009 However, a different metabolic pattern by CYP3A5 compared with CYP3A4 could possibly result in different pharmacological and/or toxicological effects of quetiapine in patients expressing CYP3A5. Quetiapine Fumarate 153-163 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 63-69 18537577-5 2008 Quetiapine is metabolized by CYP3A4, as is ziprasidone, although in the latter case aldehyde oxidase is the enzyme responsible for most of the metabolism. Quetiapine Fumarate 0-10 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 29-35 17214606-7 2007 Quetiapine is metabolized by CYP3A4, while sertindole and aripiprazole are metabolized by CYP2D6 and CYP3A4. Quetiapine Fumarate 0-10 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 29-35 15883149-2 2005 Dosage alterations of olanzapine and clozapine, dependent on cytochrome P450 1A2 (CYP1A2) for clearance, and quetiapine, dependent on cytochrome P450 3A (CYP3A), may be necessary when used with other drugs that inhibit or induce their metabolic enzymes. Quetiapine Fumarate 109-119 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 134-152 15883149-2 2005 Dosage alterations of olanzapine and clozapine, dependent on cytochrome P450 1A2 (CYP1A2) for clearance, and quetiapine, dependent on cytochrome P450 3A (CYP3A), may be necessary when used with other drugs that inhibit or induce their metabolic enzymes. Quetiapine Fumarate 109-119 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 154-159 15834460-7 2005 CYP3A4 is the primary enzyme responsible for CYP-mediated metabolism of QTP in clinical therapy dosage in vivo. Quetiapine Fumarate 72-75 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 0-6 15834460-8 2005 QTP sulfoxidation and N-dealkylation are mainly catalyzed by CYP3A4. Quetiapine Fumarate 0-3 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 61-67 21383647-11 2011 In three patients treated with potent CYP3A4 inducers, the observed C/D ratios of quetiapine and N-desalkylquetiapine were 77% and 11% lower than the mean C/D ratio in the study population, respectively. Quetiapine Fumarate 82-92 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 38-44 21383647-13 2011 Age 65 years or older and comedication with CYP3A4 inducers affected the serum levels of both agents, but the relative impact was greater on quetiapine. Quetiapine Fumarate 141-151 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 44-50 16390352-9 2006 CONCLUSIONS: Cytochrome P450 3A4 is a primary enzyme responsible for the metabolic clearance of quetiapine. Quetiapine Fumarate 96-106 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 13-32 16390352-10 2006 Quetiapine pharmacokinetics were affected by concomitant administration of ketoconazole and carbamazepine, and therefore other drugs and ingested natural products that strongly modulate the activity or expression of CYP3A4 would be predicted to change exposure to quetiapine. Quetiapine Fumarate 0-10 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 216-222 16390352-10 2006 Quetiapine pharmacokinetics were affected by concomitant administration of ketoconazole and carbamazepine, and therefore other drugs and ingested natural products that strongly modulate the activity or expression of CYP3A4 would be predicted to change exposure to quetiapine. Quetiapine Fumarate 264-274 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 216-222 16841513-3 2006 The cytochrome P450 isozymes CYP3A4 and CYP2D6 displayed activity towards quetiapine. Quetiapine Fumarate 74-84 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 29-35 16841513-4 2006 The isozyme CYP2D6 played a minor role in the metabolism of quetiapine as CYP3A4 contributed 89% to the overall metabolism. Quetiapine Fumarate 60-70 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 74-80 15570533-6 2004 CONCLUSIONS: We suppose a potential of pharmacokinetic interaction between quetiapine and ziprasidone because of the same metabolic pathway by CYP3A4. Quetiapine Fumarate 75-85 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 143-149